Novella shuffles execs as Quintiles deal pends

Two weeks after agreeing to become part of CRO giant Quintiles ($Q), Novella Clinical is promoting from within to prepare for future growth. Former business optimization and vendor management chief Deborah Turunjian will now serve as vice president of oncology development; Jamie Gault, former quality assurance head, will now helm the company's regulatory affairs division; and Kathleen Zajd, who joined Novella after its 2010 buyout of Prologue Research, will serve as vice president of global quality and compliance. Quintiles expects to close its buyout this quarter. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

Genae's CEO says the transaction reflects recent focus on digital health and data-driven services.